Status of the Claims:

1. (Original) A cancer therapeutic formulation having reduced toxicity, comprising, an effective dose of a galactomannan, and an effective dose of a chemotherapeutic agent in a mixture.

2. (Original) A cancer therapeutic formulation according to claim 1 wherein the formulation is in a powder form.

3. (Original) A cancer therapeutic formulation according to claim 1 wherein the formulation is in a liquid form.

4. (New) A pharmaceutical formulation, comprising: a mixture of galactomannan polysaccharide and an effective dose for treating cancer of a chemotherapeutic agent in a pharmaceutically acceptable formulation.

5. (New) The pharmaceutical formulation of claim 4, wherein the mixture comprises an amount of galactomannan and the chemotherapeutic agent in the ratio suitable for reducing a toxic effect in the subject , the toxic effect resulting from administration of a cancer treating amount of chemotherapeutic agent absent galactomannan.

6. (New) The pharmaceutical formulation of claim 4, wherein the mixture comprises an amount of galactomannan and the chemotherapeutic agent in a ratio suitable for enhancing efficacy of chemotherapeutic effect for treating the cancer.

7. (New) The pharmaceutical formulation of claim 4, wherein the chemotherapeutic agent is 5-FU.

8. (New) The pharmaceutical formulation of claim 4, wherein the chemotherapeutic agent is adriamycin.

9. (New) The formulation of claim 5 or 6, wherein the formulation is in a powder form.

10. (New) The formulation of claim 5 or 6, wherein the formulation is in a liquid form.